MIDDLE EAST & AFRICA SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT 2) INHIBITORS MARKET Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Middle-East and Africa Sodium-dependent Glucose Co-transporter 2 Inhibitors Market is segmented into Drug (Invokana, Jardiance, and Farxiga/Forxiga) and Geography. The report offers the value (in USD million) and volume (in Units million) for the above segments.

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Size

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Summary

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Analysis

The MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size is estimated at USD 180.64 million in 2025, and is expected to reach USD 279.86 million by 2030, at a CAGR of 9.15% during the forecast period (2025-2030).

The COVID-19 pandemic positively impacted the Asia-Pacific Sodium-Dependent Glucose Cotransporter 2 market. People with diabetes have a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people. The manufacturers of diabetes drugs have taken care during COVID-19 to deliver the medications to diabetes patients with the help of local governments. NovoNordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.'

The Market is increasing mainly due to the drugs Jardiance and Farxiga/Forxiga. Jardiance is a once-daily oral medication that is used to control blood glucose levels in people suffering from type-2 diabetes. Patients prefer this drug, as it has a lesser risk of cardiovascular diseases when compared to other SGLT 2 class of drugs. The number of diabetic patients in Middle-East and Africa is increasing immensely over the past few years due to factors, including the increasing geriatric population in the region and the increase in the overweight and obese population, owing to unhealthy diets and physical inactivity. As diabetes can potentially increase the risk of cardiovascular diseases, it needs to be managed well by seeking suitable treatments at regular intervals of time.

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Industry Overview

The SGLT 2 inhibitors market is highly consolidated, with a few significant manufacturers having a Middle East and Africa market presence. The joint ventures between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim manufacture Jardiance, a popular SGLT 2 class drug.

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Leaders

  1. Astrazeneca

  2. Bristol-Myers Squibb

  3. Eli Lilly

  4. Janssen

  5. Astellas

  6. *Disclaimer: Major Players sorted in no particular order
MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market News

  • April 2022: The sodium-glucose co-transporter-2 (SGLT2) inhibitor, sold as Jardiance, joins Dapagliflozin (sold as Forxiga) as the second medicine of this class to be approved for use in heart failure (HF).
  • March 2022: A study by the Journal of Medical Economics, Egypt, stated that Dapagliflozin was found to be a highly cost-effective and cost-saving medication when compared to SOC and sacubitril/valsartan, respectively, in the treatment of HF-rEF from the Egyptian healthcare system perspective.

MEA Sodium-Dependent Glucose Co-Transporter 2 Inhibitors Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Inhibitor
    • 5.1.1.1 Invokana (Canagliflozin)
    • 5.1.1.2 Jardiance (Empagliflozin)
    • 5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
  • 5.2 Geography
    • 5.2.1 Saudi Arabia
    • 5.2.2 Iran
    • 5.2.3 Egypt
    • 5.2.4 Oman
    • 5.2.5 South Africa
    • 5.2.6 Rest of Middle-East and Africa

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Eli Lilly
    • 7.1.2 Janssen Pharmaceuticals
    • 7.1.3 Boehringer Ingelheim
    • 7.1.4 AstraZeneca
    • 7.1.5 Bristol Myers Squibb
  • *List Not Exhaustive
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 Eli Lilly
    • 7.2.2 Janssen Pharmaceuticals
    • 7.2.3 Boehringer Ingelheim
    • 7.2.4 AstraZeneca

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products andĀ Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Industry Segmentation

SGLT2 inhibitors are a class of prescription medicines that are FDA-authorized to be used with diet and exercise to decrease blood sugar in adults with type 2 diabetes. Middle-East and Africa, Sodium-dependent Glucose Co-transporter 2 Inhibitors Market, Witnessed USD 135 million in the current year and is anticipated to register a CAGR of over 11% during the forecast period. Middle-East and Africa Sodium-dependent Glucose Co-transporter 2 Inhibitors Market is Segmented into Drug (Invokana, Jardiance, and Farxiga/Forxiga) and Geography. The report offers the value (in USD million) and volume (in Units million) for the above segments. We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.

Drug Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Inhibitor Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Geography Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle-East and Africa
Drug
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Inhibitor Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Geography
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle-East and Africa
Need A Different Region or Segment?
Customize Now

MEA Sodium-Dependent Glucose Co-Transporter 2 Inhibitors Market Research FAQs

How big is the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market?

The MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size is expected to reach USD 180.64 million in 2025 and grow at a CAGR of 9.15% to reach USD 279.86 million by 2030.

What is the current MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size?

In 2025, the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size is expected to reach USD 180.64 million.

Who are the key players in MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market?

Astrazeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and Astellas are the major companies operating in the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market.

What years does this MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market cover, and what was the market size in 2024?

In 2024, the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size was estimated at USD 164.11 million. The report covers the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Industry Report

Statistics for the 2025 MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Report Snapshots

Compare market size and growth of MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market with other markets in Healthcare Industry

Access Report long-arrow-right